Xtant Medical Holdings, Inc. XTNT
Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Management's Discussion and Analysis of Financial Condition and Results of Operations
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- United States
- Non-US
| Region | FY2025 | FY2024 |
|---|---|---|
| United States | $122.4M | $105.5M |
| Non-US | $11.5M | $11.7M |
As the company reported it, from the “Schedule of Revenues by Geographic Region (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $133.9M | $117.3M | $91.3M | $58.0M | $55.3M | $53.3M | $64.7M | $72.2M | $82.5M | $90.0M |
| Cost of revenue | $49.7M | $49.1M | $35.8M | $25.8M | $22.8M | $18.9M | $22.2M | $28.7M | $32.5M | $27.7M |
| Gross profit | $84.3M | $68.2M | $55.5M | $32.1M | $32.5M | $34.4M | $42.5M | $43.5M | $50.1M | $62.3M |
| R&D | $2.1M | $2.4M | $1.3M | $915.0K | $870.0K | $657.0K | $932.0K | $1.7M | $2.4M | $3.4M |
| SG&A | $29.4M | $28.7M | $25.9M | $15.5M | $14.4M | $13.5M | $17.3M | $14.3M | $15.2M | $15.8M |
| Total operating expenses | $77.0M | $80.3M | $65.6M | $38.9M | $36.3M | $35.1M | $44.8M | $103.6M | $87.9M | $69.8M |
| Operating income | $7.3M | -$12.1M | -$10.2M | -$6.8M | -$3.9M | -$751.0K | -$2.3M | -$60.1M | -$37.8M | -$7.5M |
| Interest expense | $3.7M | $4.2M | $2.9M | $1.7M | $995.0K | $6.0M | $5.8M | $10.1M | $14.7M | $12.3M |
| Pre-tax income | $7.0M | -$16.3M | -$1.0M | -$8.4M | -$4.8M | -$6.7M | -$8.1M | -$70.1M | -$52.4M | -$19.4M |
| Income tax | $2.0M | $187.0K | $1.7M | $69.0K | — | $296.0K | $98.0K | — | $0 | $50.4K |
| Net income | $5.0K | -$16.4K | $660 | -$8.5M | -$4.8M | -$7.0M | -$8.2M | -$70.1M | -$52.4M | -$19.5M |
| EPS, basic | 0.04 | -0.12 | 0.01 | -0.09 | -0.06 | -0.25 | -0.63 | -5.97 | -34.76 | -18.46 |
| EPS, diluted | 0.03 | -0.12 | 0.01 | -0.09 | -0.06 | -0.25 | -0.63 | -5.97 | -34.76 | -18.46 |
| Shares, diluted (wtd. avg.) | 150.0M | 133.7M | 126.8M | 94.1M | 85.5M | 28.5M | 13.2M | 11.7M | 1.5M | 1.1M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $17.1M | $6.2M | $5.7M | $20.3M | $18.2M | $2.3M | $5.2M | $6.8M | $2.9M | $2.6M |
| Receivables | $17.8M | $20.7M | $21.7M | $10.9M | $7.2M | $6.9M | $10.1M | $10.0M | $12.7M | $19.0M |
| Inventory | $30.3M | $38.6M | $36.9M | $17.3M | $17.9M | $21.4M | $16.1M | $17.3M | $22.4M | $26.3M |
| Total current assets | $78.2M | $67.1M | $64.9M | $49.3M | $44.3M | $31.4M | $32.2M | $34.7M | $39.7M | $49.0M |
| Property, plant and equipment | $6.2M | $10.1M | $8.7M | $5.8M | $5.2M | $4.3M | $4.7M | $7.2M | $9.9M | $15.8M |
| Goodwill | $6.1M | $7.3M | $7.3M | $3.2M | $3.2M | $3.2M | $3.2M | $3.2M | $41.5M | $41.5M |
| Other intangibles | $299.0K | $8.4M | $10.1M | $344.0K | $400.0K | $457.0K | $515.0K | $573.0K | $13.8M | $35.9M |
| Total assets | $94.1M | $93.8M | $92.6M | $60.2M | $54.7M | $41.5M | $43.2M | $46.4M | $105.7M | $144.1M |
| Accounts payable | $3.8M | $7.9M | $7.1M | $3.5M | $2.6M | $2.9M | $2.2M | $6.5M | $9.3M | $10.5M |
| Short-term debt | $3.5M | — | — | $2.3M | — | $16.8M | — | — | — | — |
| Total current liabilities | $29.5M | $28.6M | $23.0M | $15.2M | $11.1M | $25.6M | $9.4M | $12.1M | $25.8M | $31.1M |
| Long-term debt | $11.0M | $22.0M | $17.2M | $9.7M | $11.8M | — | $76.2M | $77.9M | $67.1M | $119.2M |
| Total liabilities | $43.2M | $50.9M | $41.3M | $26.1M | $23.8M | $27.0M | $87.4M | $90.2M | $164.4M | $151.2M |
| Retained earnings | -$254.5M | -$259.5M | -$243.0M | -$243.7M | -$235.2M | -$230.3M | -$223.3M | -$215.0M | -$144.9M | -$92.5M |
| Total equity | $51.0M | $43.0M | $51.3M | $34.2M | $30.9M | $14.5M | -$44.2M | -$43.8M | -$58.7M | -$7.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $12.5M | -$11.9M | -$9.5M | -$5.3M | $439.0K | -$731.0K | -$413.0K | $1.2M | -$543.0K | -$14.4M |
| Depreciation and amortisation | $5.2M | $4.2M | $3.2M | $1.3M | $1.3M | $2.1M | $3.1M | $6.6M | $8.4M | $7.2M |
| Stock-based compensation | $2.9M | $4.1M | $2.7M | $2.5M | $2.2M | $1.1M | $515.0K | $694.0K | $212.0K | $523.0K |
| Capital expenditure | $2.4M | $4.1M | $1.5M | $1.8M | $2.1M | $1.5M | $879.0K | $624.0K | $1.6M | $5.8M |
| Investing cash flow | $7.9M | -$3.7M | -$24.8M | -$1.6M | -$1.9M | -$1.3M | -$544.0K | -$367.0K | -$1.6M | -$5.8M |
| Financing cash flow | -$9.6M | $16.1M | $19.7M | $9.0M | $17.5M | -$861.0K | -$603.0K | $3.1M | $2.4M | $16.4M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-029699.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $90.0M | $82.5M | $72.2M | $64.7M | $53.3M | $55.3M | $58.0M | $91.3M | $117.3M | $133.9M |
| Gross profit | $62.3M | $50.1M | $43.5M | $42.5M | $34.4M | $32.5M | $32.1M | $55.5M | $68.2M | $84.3M |
| Net income | -$19.5M | -$52.4M | -$70.1M | -$8.2M | -$7.0M | -$4.8M | -$8.5M | $660 | -$16.4K | $5.0K |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event Item 8.01
- Other event Item 8.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Debt acceleration or default Something has triggered a lender's right to demand early repayment - usually a covenant breach. Item 2.04
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |